Reuters logo
BRIEF-Ovid Therapeutics Announces OV101 Shows Comparable Pk Profile In Phase 1 Study Of Adolescent Patients
November 28, 2017 / 9:07 PM / in 13 days

BRIEF-Ovid Therapeutics Announces OV101 Shows Comparable Pk Profile In Phase 1 Study Of Adolescent Patients

Nov 28 (Reuters) - Ovid Therapeutics Inc:

* OVID THERAPEUTICS ANNOUNCES OV101 SHOWS COMPARABLE PK PROFILE IN PHASE 1 STUDY OF ADOLESCENT PATIENTS AND AMENDS PHASE 2 STARS CLINICAL TRIAL PROTOCOL TO INCLUDE ADOLESCENTS

* OVID THERAPEUTICS INC - ‍ANTICIPATES DATA FROM STARS TRIAL TO BE AVAILABLE IN SECOND HALF OF 2018​

* OVID THERAPEUTICS INC - ‍RESULTS FROM PHASE 1 CLINICAL TRIAL OF ADOLESCENTS WITH ANGELMAN AND FRAGILE X SYNDROMES DEMONSTRATED OV101 WAS WELL TOLERATED​

* OVID THERAPEUTICS INC - ‍IN TRIAL, OV101 WAS FOUND TO BE GENERALLY SAFE AND WELL TOLERATED​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below